Executive Functions and Dysfunction in Brain Health and Brain Disorders: Dates announced for Dr. Elkhonon Goldberg’s Symposium in Costa Rica

We are pleased to announce a fan­tas­tic 5‑day pro­fes­sion­al devel­op­ment oppor­tu­ni­ty fea­tur­ing our Advi­sor and renowned author and neu­ropsy­chol­o­gist Elkhonon Gold­berg, Ph.D., ABPP., and titled “Exec­u­tive Func­tions and Dys­func­tion in Brain Health and Brain Dis­or­ders. Frontal Lobes, Dis­trib­uted Net­works, and the Whole Brain.” The infor­ma­tion pre­sent­ed will aid prac­ti­tion­ers and researchers alike in advanc­ing their knowledge…

Read More

Best books offering brain teasers and puzzles according to ChatSpot and ChatGPT

Hav­ing recent­ly queried Chat­G­PT and ChatSpot about sug­ges­tions for books on brain health, cog­ni­tive fit­ness, cog­ni­tive abil­i­ty and skills, we decid­ed to ask about best books offer­ing brain teasers and puz­zles so that inter­est­ed read­ers can expand their cog­ni­tive exer­cise resources. (Links open cor­re­spond­ing Ama­zon book pages) Best books with brain teasers and puz­zles, per ChatSpot:…

Read More

Best books on cognitive ability and skills according to ChatSpot and ChatGPT

As a fol­low-up to the arti­cle Best books on brain health and cog­ni­tive fit­ness accord­ing to ChatSpot and Chat­G­PT we decid­ed to find out what these pop­u­lar AI chat­bots say about books to under­stand and improve cog­ni­tive abil­i­ty and skills. Here you are: (Links open cor­re­spond­ing Ama­zon book pages) Best books on cog­ni­tive abil­i­ty and skills, per…

Read More

Best books on brain health and cognitive fitness according to ChatSpot and ChatGPT

Out of curios­i­ty we queried a cou­ple pop­u­lar AI chat­bots, ChatSpot and Chat­G­PT free ver­sions, about the best books in a cou­ple of key top­ics we dis­cuss a lot in this blog. Here are the fas­ci­nat­ing results, and some brief com­men­tary at the end. (Links open cor­re­spond­ing Ama­zon book pages.) Best books on brain health, per…

Read More

Systematic review finds more clinical harm than benefits in Alzheimer’s “treatments” lecanemab, aducanumab, and donanemab

Study ques­tions ben­e­fit of new Alzheimer’s drug (UGA Today): Last sum­mer, the U.S. Food and Drug Admin­is­tra­tion ful­ly approved the first drug shown to slow the progress of Alzheimer’s. But new research from the Uni­ver­si­ty of Geor­gia sug­gests that patients and care­givers may not expe­ri­ence any ben­e­fit from the drug in their dai­ly lives. The drug, Leqembi,…

Read More